A combination of three fully human toxin A- and toxin B-specific monoclonal antibodies protects against challenge with highly virulent epidemic strains of clostridium difficile in the hamster model

Clinical and Vaccine Immunology

Volumn 22, Issue 7, 2015, Pages 711-725

  Anosova, Natalie G ^a   Cole, Leah E ^a   Li, Lu ^a   Zhang, Jinrong ^a   Brown, Anna M ^a   Mundle, Sophia ^a   Zhang, Jianxin ^a   Ray, Satyajit ^a   Ma, Fuqin ^a   Garrone, Pierre ^b   Bertraminelli, Nicola ^b   Kleanthous, Harry ^a   Anderson, Stephen F ^a  

^a Sanofi Pasteur Biologics Co   (United States)

^b BliNK Biomedical SAS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY A1; MONOCLONAL ANTIBODY A2; MONOCLONAL ANTIBODY A3; MONOCLONAL ANTIBODY A4; MONOCLONAL ANTIBODY A5; MONOCLONAL ANTIBODY B1; MONOCLONAL ANTIBODY B2; MONOCLONAL ANTIBODY B3; MONOCLONAL ANTIBODY B4; MONOCLONAL ANTIBODY B5; MONOCLONAL ANTIBODY B6; UNCLASSIFIED DRUG; ANTITOXIN; BACTERIAL PROTEIN; BACTERIAL TOXIN; BACTERIUM ANTIBODY; ENTEROTOXIN; TCDA PROTEIN, CLOSTRIDIUM DIFFICILE; TOXB PROTEIN, CLOSTRIDIUM DIFFICILE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL STRAIN; BINDING AFFINITY; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; EPITOPE MAPPING; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MORTALITY; NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE; SYRIAN HAMSTER; VERO CELL LINE; ANIMAL; ANTAGONISTS AND INHIBITORS; CLOSTRIDIUM INFECTIONS; DISEASE MODEL; HUMAN; IMMUNOLOGY; MESOCRICETUS; PATHOLOGY; PEPTOCLOSTRIDIUM DIFFICILE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODIES, MONOCLONAL; ANTITOXINS; BACTERIAL PROTEINS; BACTERIAL TOXINS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; DIARRHEA; DISEASE MODELS, ANIMAL; ENTEROTOXINS; FEMALE; HUMANS; MESOCRICETUS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84936873049     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00763-14     Document Type: Article

References (46)

1. Rupnik M, Wilcox MH, Gerding DN. 2009. Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat Rev Microbiol 7:526-536. http://dx.doi.org/10.1038/nrmicro2164.
2. Le Monnier A, Zahar JR, Barbut F. 2014. Update on Clostridium difficile infections. Med Mal Infect 44:354-365. http://dx.doi.org/10.1016/j.medmal.2014.04.002.
3. Dawson LF, Valiente E, Donahue EH, Birchenough G, Wren BW. 2011. Hypervirulent Clostridium difficile PCR-ribotypes exhibit resistance to widely used disinfectants. PLoS One 6:e25754. http://dx.doi.org/10.1371/journal.pone.0025754.
4. Gerding DN, Muto CA, Owens RC, Jr. 2008. Measures to control and prevent Clostridium difficile infection. Clin Infect Dis 46(Suppl 1):S43-S49. http://dx.doi.org/10.1086/521861.
5. Lawley TD, Clare S, Deakin LJ, Goulding D, Yen JL, Raisen C, Brandt C, Lovell J, Cooke F, Clark TG, Dougan G. 2010. Use of purified Clostridium difficile spores to facilitate evaluation of health care disinfection regimens. Appl Environ Microbiol 76:6895-6900. http://dx.doi.org/10.1128/AEM.00718-10.
6. Deakin LJ, Clare S, Fagan RP, Dawson LF, Pickard DJ, West MR, Wren BW, Fairweather NF, Dougan G, Lawley TD. 2012. The Clostridium difficile spo0A gene is a persistence and transmission factor. Infect Immun 80:2704-2711. http://dx.doi.org/10.1128/IAI.00147-12.
7. Kuijper EJ, Coignard B, Tüll P, ESCMID Study Group for Clostridium difficile; EU Member States, European Centre for Disease Prevention and Control. 2006. Emergence of Clostridium difficile-associated disease in North America and Europe. Clin Microbiol Infect 12(Suppl 6):S2-S18. http://dx.doi.org/10.1111/j.1469-0691.2006.01580.x.
8. Miller M, Gravel D, Mulvey M, Taylor G, Boyd D, Simor A, Gardam M, McGeer A, Hutchinson J, Moore D, Kelly S. 2010. Health careassociated Clostridium difficile infection in Canada: patient age and infecting strain type are highly predictive of severe outcome and mortality. Clin Infect Dis 15:194-201. http://dx.doi.org/10.1086/649213.
9. Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, Pepin J, Wilcox MH, Society for Healthcare Epidemiology of America, Infectious Diseases Society of America. 2010. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 31:431-455. http://dx.doi.org/10.1086/651706.
10. Peterfreund GL, Vandivier LE, Sinha R, Marozsan AJ, Olson WC, Zhu J, Bushman FD. 2012. Succession in the gut microbiome following antibiotic and antibody therapies for Clostridium difficile. PLoS One 7:e46966. http://dx.doi.org/10.1371/journal.pone.0046966.
11. Voth DE, Ballard JD. 2005. Clostridium difficile toxins: mechanism of action and role in disease. Clin Microbiol Rev 18:247-263. http://dx.doi.org/10.1128/CMR.18.2.247-263.2005.
12. Tonna I, Welsby PD. 2005. Pathogenesis and treatment of Clostridium difficile infection. Postgrad Med J 81:367-369. http://dx.doi.org/10.1136/pgmj.2004.028480.
13. Kuehne SA, Cartman ST, Heap JT, Kelly ML, Cockayne A, Minton NP. 2010. The role of toxin A and toxin B in Clostridium difficile infection. Nature 467:711-714. http://dx.doi.org/10.1038/nature09397.
14. Bacci S, M?lbak K, Kjeldsen MK, Olsen KE. 2011. Binary toxin and death after Clostridium difficile infection. Emerg Infect Dis 17:976-982. http://dx.doi.org/10.3201/eid/1706.101483.
15. Kuehne SA, Collery MM, Kelly ML, Cartman ST, Cockayne A, Minton NP. 2014. Importance of toxin A, toxin B, and CDT in virulence of an epidemic Clostridium difficile strain. J Infect Dis 209:83-86. http://dx.doi.org/10.1093/infdis/jit426.
16. Heinrichs JH. 2012. Design, production and pre-clinical evaluation of a novel toxin-based vaccine for the prevention of Clostridium difficile disease, p 30. International Clostridium difficile Symposium, 20 to 22 September 2012, Bled, Slovenia.
17. Lowy I, Molrine DC, Leav BA, Blair BM, Baxter R, Gerding DN, Nichol G, Thomas WD, Jr, Leney M, Sloan S, Hay CA, Ambrosino DM. 2010. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med 362:197-205. http://dx.doi.org/10.1056/NEJMoa0907635.
18. Gerding DN, Johnson S. 2010. Management of Clostridium difficile infection: thinking inside and outside the box. Clin Infect Dis 51:1306-1313. http://dx.doi.org/10.1086/657116.
19. Gerding DN. 2012. Clostridium difficile infection prevention: biotherapeutics, immunologics, and vaccines. Discov Med 13:75-83.
20. Anosova NG, Brown AM, Li L, Liu N, Cole LE, Zhang J, Mehta H, Kleanthous H. 2013. Systemic antibody responses induced by a twocomponent Clostridium difficile toxoid vaccine protect against C. Difficileassociated disease in hamsters. J Med Microbiol 62(Pt 9):1394-1404. http://dx.doi.org/10.1099/jmm.0.056796-0.
21. Greenberg RN, Marbury T, Foglia G, Warny M. 2012. Phase I dose finding studies of an adjuvanted Clostridium difficile toxoid vaccine. Vaccine 30:2245-2249. http://dx.doi.org/10.1016/j.vaccine.2012.01.065.
22. Foglia G, Shah S, Luxemburger C, Pietrobon PJ. 2012. Clostridium difficile: development of a novel candidate vaccine. Vaccine 30:4307-4309. http://dx.doi.org/10.1016/j.vaccine.2012.01.056.
23. Permpoonpattana P, Hong HA, Phetcharaburanin J, Huang JM, Cook J, Fairweather NF, Cutting SM. 2011. Immunization with Bacillus spores expressing toxin A peptide repeats protects against infection with Clostridium difficile strains producing toxins A and B. Infect Immun 79:2295-2302. http://dx.doi.org/10.1128/IAI.00130-11.
24. Tian JH, Fuhrmann SR, Kluepfel-Stahl S, Carman RJ, Ellingsworth L, Flyer DC. 2012. A novel fusion protein containing the receptor binding domains of C. Difficile toxin A and toxin B elicits protective immunity against lethal toxin and spore challenge in preclinical efficacy models. Vaccine 30:4249-4258. http://dx.doi.org/10.1016/j.vaccine.2012.04.045.
25. Karczewski J, Zorman J, Wang S, Miezeiewski M, Xie J, Soring K, Petrescu I, Rogers I, Thiriot DS, Cook JC, Chamberlin M, Xoconostle RF, Nahas DD, Joyce JG, Bodmer JL, Heinrichs JH, Secore S. 2014. Development of a recombinant toxin fragment vaccine for Clostridium difficile infection. Vaccine 32:2812-2818. http://dx.doi.org/10.1016/j.vaccine.2014.02.026.
26. Kyne L, Warny M, Quamar A, Kelly CP. 2000. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med 342:390-397. http://dx.doi.org/10.1056/NEJM200002103420604.
27. Kyne L, Warny M, Quamar A, Kelly CP. 2001. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 357:189-193. http://dx.doi.org/10.1016/S0140 -6736(00)03592-3.
28. Aronsson B, Granström M, Möllby R, Nord CE. 1985. Serum antibody response to Clostridium difficile toxins in patients with Clostridium difficile diarrhoea. Infection 13:97-101. http://dx.doi.org/10.1007/BF01642866.
29. Marozsan AJ, Ma D, Nagashima KA, Kennedy BJ, Kang YK, Arrigale RR, Donovan GP, Magargal WW, Maddon PJ, Olson WC. 2012. Protection against Clostridium difficile infection with broadly neutralizing antitoxin monoclonal antibodies. J Infect Dis 206:706-713. http://dx.doi.org/10.1093/infdis/jis416.
30. Davies NL, Compson JE, MacKenzie B, O?Dowd VL, Oxbrow AK, Heads JT, Turner A, Sarkar K, Dugdale SL, Jairaj M, Christodoulou L, Knight DE, Cross AS, Hervé KJ, Tyson KL, Hailu H, Doyle CB, Ellis M, Kriek M, Cox M, Page MJ, Moore AR, Lightwood DJ, Humphreys DP. 2013. A mixture of functionally oligoclonal humanized monoclonal antibodies that neutralize Clostridium difficile TcdA and TcdB with high levels of in vitro potency shows in vivo protection in a hamster infection model. Clin Vaccine Immunol 20:377-390. http://dx.doi.org/10.1128/CVI.00625-12.
31. Hussack G, Arbabi-Ghahroudi M, van Faassen H, Songer JG, Ng KK, MacKenzie R, Tanha J. 2011. Neutralization of Clostridium difficile toxin A with single-domain antibodies targeting the cell receptor binding domain. Biol Chem 286:8961-8976. http://dx.doi.org/10.1074/jbc.M110.198754.
32. Zhang C, Jin K, Xiao Y, Cheng Y, Huang Z, Wang S, Lu S. 2013. Potent monoclonal antibodies against Clostridium difficile toxin A elicited by DNA immunization. Hum Vaccin Immunother 9:2157-2164. http://dx.doi.org/10.4161/hv.25656.
33. Demarest SJ, Hariharan M, Elia M, Salbato J, Jin P, Bird C, Short JM, Kimmel BE, Dudley M, Woodnutt G, Hansen G. 2010. Neutralization of Clostridium difficile toxin A using antibody combinations. MAbs 2:190-198. http://dx.doi.org/10.4161/mabs.2.2.11220.
34. Babcock GJ, Broering TJ, Hernandez HJ, Mandell RB, Donahue K, Boatright N, Stack AM, Lowy I, Graziano R, Molrine D, Ambrosino DM, Thomas WD, Jr. 2006. Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters. Infect Immun 74:6339-6347. http://dx.doi.org/10.1128/IAI.00982-06.
35. Rupnik M. 2008. Heterogeneity of large clostridial toxins: importance of Clostridium difficile toxinotypes. FEMS Microbiol Rev 32:541-555. http://dx.doi.org/10.1111/j.1574-6976.2008.00110.x.
36. Cheknis AK, Sambol SP, Davidson DM, Nagaro KJ, Mancini MC, Hidalgo-Arroyo GA, Brazier JS, Johnson S, Gerding DN. 2009. Distribution of Clostridium difficile strains from a North American, European and Australian trial of treatment for C. Difficile infections: 2005-2007. Anaerobe 15:230-233. http://dx.doi.org/10.1016/j.anaerobe.2009.09.001.
37. Stabler RA, Dawson LF, Valiente E, Cairns MD, Martin MJ, Donahue EH, Riley TV, Songer JG, Kuijper EJ, Dingle KE, Wren BW. 2012. Macro and micro diversity of Clostridium difficile isolates from diverse sources and geographical locations. PLoS One 7:e31559. http://dx.doi.org/10.1371/journal.pone.0031559.
38. Balassiano IT, Yates EA, Domingues RM, Ferreira EO. 2012. Clostridium difficile: a problem of concern in developed countries and still a mystery in Latin America. J Med Microbiol 61(Pt 2):169-179. http://dx.doi.org/10.1099/jmm.0.037077-0.
39. Kink JA, Williams JA. 1998. Antibodies to recombinant Clostridium difficile toxins A and B are an effective treatment and prevent relapse of C. Difficile-associated disease in a hamster model of infection. Infect Immun 66:2018-2025.
40. Korbie DJ, Mattick JS. 2008. Touchdown PCR for increased specificity and sensitivity in PCR amplification. Nat Protoc 3:1452-1456. http://dx.doi.org/10.1038/nprot.2008.133.
41. Stubbe H, Berdoz J, Kraehenbuhl J, Corthesy B. 2000. Polymeric IgA is superior to monomeric IgA and IgG carrying the same variable domain in preventing Clostridium difficile toxin A damaging of T84 monolayers. J Immunol 164:1952-1960. http://dx.doi.org/10.4049/jimmunol.164.4.1952.
42. Warny M, Pepin J, Fang A, Killgore G, Thompson A, Brazier J, Frost E, McDonald LC. 2005. Toxin production by and emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 366:1079-1084.
43. Razaq N, Sambol S, Nagaro K, Zukowski W, Cheknis A, Johnson S, Gerding DN. 2007. Infection of hamsters with historical and epidemic BI types of Clostridium difficile. J Infect Dis 196:1813. http://dx.doi.org/10.1086/523106.
44. Steele J, Mukherjee J, Parry N, Tzipori S. 2013. Antibody against toxin TcdB, but not toxin TcdA, prevents development of gastrointestinal and systemic Clostridium difficile disease. J Infect Dis 207:323-330. http://dx.doi.org/10.1093/infdis/jis669.
45. Lyras D, O?Connor JR, Howarth PM, Sambol SP, Carter GP, Phumoonna T, Poon R, Adams V, Vedantam G, Johnson S, Gerding DN, Rood JI. 2009. Toxin B is essential for virulence of Clostridium difficile. Nature 458:1176-1179. http://dx.doi.org/10.1038/nature07822.
46. Leav BA, Blair B, Leney M, Knauber M, Reilly C, Lowy I, Gerding DN, Kelly CP, Katchar K, Baxter R, Ambrosino D, Molrine D. 2010. Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI). Vaccine 28:965-969. http://dx.doi.org/10.1016/j.vaccine.2009.10.144.